Patient characteristics
. | IFN . | ASCT . | Total . |
|---|---|---|---|
| Patients evaluable, no. | 60 | 62 | 122 |
| Median age of evaluable patients in years (range) | 55.2 (37-65) | 55.6 (35-65) | 55.6 (35-65) |
| IPI, n = 108 (%) | |||
| Low-risk | 22 (42) | 24 (44) | 46 (43) |
| Low-intermediate risk | 23 (43) | 21 (38) | 44 (41) |
| High-intermediate risk | 6 (11) | 6 (11) | 12 (11) |
| High-risk | 2 (4) | 4 (7) | 6 (6) |
| Male (%) | 42 (70) | 48 (77) | 90 (74) |
| Stage IV (%) | 47 (78) | 52 (84) | 99 (81) |
| Elevated serum LDH, n = 111 (%) | 14 (26) | 14 (25) | 28 (25) |
| ECOG score greater than 1 (%) | 3 (5) | 2 (3) | 5 (4) |
| B-symptoms (%) | 20 (33) | 25 (40) | 45 (37) |
| Induction therapy (%) | |||
| CHOP | 35 (58) | 39 (63) | 74 (61) |
| R-CHOP | 14 (23) | 18 (29) | 32 (26) |
| Other CHOP-like regimens | 11 (18) | 5 (8) | 16 (13) |
. | IFN . | ASCT . | Total . |
|---|---|---|---|
| Patients evaluable, no. | 60 | 62 | 122 |
| Median age of evaluable patients in years (range) | 55.2 (37-65) | 55.6 (35-65) | 55.6 (35-65) |
| IPI, n = 108 (%) | |||
| Low-risk | 22 (42) | 24 (44) | 46 (43) |
| Low-intermediate risk | 23 (43) | 21 (38) | 44 (41) |
| High-intermediate risk | 6 (11) | 6 (11) | 12 (11) |
| High-risk | 2 (4) | 4 (7) | 6 (6) |
| Male (%) | 42 (70) | 48 (77) | 90 (74) |
| Stage IV (%) | 47 (78) | 52 (84) | 99 (81) |
| Elevated serum LDH, n = 111 (%) | 14 (26) | 14 (25) | 28 (25) |
| ECOG score greater than 1 (%) | 3 (5) | 2 (3) | 5 (4) |
| B-symptoms (%) | 20 (33) | 25 (40) | 45 (37) |
| Induction therapy (%) | |||
| CHOP | 35 (58) | 39 (63) | 74 (61) |
| R-CHOP | 14 (23) | 18 (29) | 32 (26) |
| Other CHOP-like regimens | 11 (18) | 5 (8) | 16 (13) |
The distribution of patient characteristics is well balanced between both study arms.
IFN indicates α-interferon maintenance; ASCT, autologous stem cell transplantation; IPI, International Prognostic Index; n, number of patients; and ECOG, Eastern Cooperative Oncology Group.